TrialThe oncologist2023

Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.

Keiko Tanimura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.